From the Research
Pidotimod is effective in preventing respiratory infections, particularly in children with recurrent and frequent infectious episodes, as evidenced by the most recent study in 2024 1. The effectiveness of pidotimod can be attributed to its immunomodulatory activity, which modifies innate and adaptive immunity, and its ability to affect immunoglobulin production and their switching. Some key points about pidotimod include:
- It is a synthetic dipeptide that exerts immunomodulatory activity, modifying innate and adaptive immunity 1
- It can reduce the frequency, duration, and severity of respiratory infections, with some patients experiencing fewer infections during treatment periods 2, 3
- The typical dosage is 400 mg daily for children, usually administered for 2-3 months 4
- It is generally well-tolerated with minimal side effects, mainly mild gastrointestinal disturbances 5
- Pidotimod should be used as part of a comprehensive approach to managing recurrent infections rather than as a standalone treatment, and patients should maintain realistic expectations about its benefits 1, 2
- The most recent and highest quality study, published in 2024, provides strong evidence for the effectiveness of pidotimod in preventing respiratory infections in children 1